BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schultheiss JPD, Mahmoud R, Louwers JM, van der Kaaij MT, van Hellemondt BP, van Boeckel PG, Mahmmod N, Jharap B, Fidder HH, Oldenburg B. Loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2021;54:1298-308. [PMID: 34559428 DOI: 10.1111/apt.16605] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Thomas PWA, van Caem M, West RL, Russel MGVM, Jansen JM, Römkens TEH, Hoentjen F; IBDREAM registry. Long-term effectiveness and safety of ustekinumab in Crohn's disease: a prospective cohort study. Eur J Gastroenterol Hepatol 2023;35:261-9. [PMID: 36708296 DOI: 10.1097/MEG.0000000000002506] [Reference Citation Analysis]
2 Savelkoul EHJ, Thomas PWA, Derikx LAAP, den Broeder N, Römkens TEH, Hoentjen F. Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac200. [PMID: 36318229 DOI: 10.1093/ibd/izac200] [Reference Citation Analysis]
3 Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, Laugie M, Manlay L, Mathieu N, Pereira B, Fumery M. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00776-5. [PMID: 35987302 DOI: 10.1016/j.cgh.2022.08.011] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Buhl S, Steenholdt C, Brynskov J, Christensen KR, Dorn-rasmussen M, Thomsen OØ, Bendtzen K, Klausen TW, Dahlerup JF, Thorsgaard N, Jahnsen J, Molazahi A, Pedersen N, Kjeldsen J, Almer S, Dahl EE, Vind I, Cannon AG, Marsal J, Sipponen T, Agnholt JS, Kievit HAL, Aure SL, Martinsen L, Meisner S, Hansen JM, Ainsworth MA. Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease. NEJM Evidence 2022;1. [DOI: 10.1056/evidoa2200061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
5 Alsoud D, Verstockt B, Vermeire S. Letter: immunogenicity is not the root cause for loss of response to anti-TNF agents in patients with IBD in TDM era. Aliment Pharmacol Ther 2022;55:885-6. [PMID: 35315101 DOI: 10.1111/apt.16797] [Reference Citation Analysis]
6 Mahmoud R, Schultheiss JPD, Fidder HH, Oldenburg B. Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply. Aliment Pharmacol Ther 2022;55:499-500. [PMID: 35092052 DOI: 10.1111/apt.16757] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ben-Horin S, Ungar B. Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment duration. Aliment Pharmacol Ther 2022;55:497-8. [PMID: 35092047 DOI: 10.1111/apt.16713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Papamichael K, Cheifetz AS. Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology. [DOI: 10.1080/17425255.2021.2027367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Schultheiss JPD, Mahmoud R, Fidder HH, Oldenburg B. Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases - the longer the less? Authors' reply. Aliment Pharmacol Ther 2022;55:246. [PMID: 34970765 DOI: 10.1111/apt.16722] [Reference Citation Analysis]
10 Goren I, Yanai H. Editorial: risk of loss of response to anti-TNFα agents in patients with inflammatory bowel disease-the longer the less? Aliment Pharmacol Ther 2022;55:244-5. [PMID: 34970768 DOI: 10.1111/apt.16648] [Reference Citation Analysis]